Home/Pipeline/AMD112

AMD112

RNA delivery for gene editing

PreclinicalActive

Key Facts

Indication
RNA delivery for gene editing
Phase
Preclinical
Status
Active
Company

About Holy Stone Healthcare

Taiwan biotech leveraging hyaluronic‑acid biopolymers for targeted brain, eye, and tumor drug delivery.

View full company profile